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http://www.biomedcentral.com/1471-2407/12/592RESEARCH ARTICLE Open AccessIntraoperative Electron Radiation Therapy (IOERT)
in the management of locally recurrent rectal
cancer
Falk Roeder1,2*, Joerg-Michael Goetz1,2, Gregor Habl2, Marc Bischof2, Robert Krempien3, Markus W Buechler4,
Frank W Hensley2, Peter E Huber1,2, Juergen Weitz4 and Juergen Debus1,2Abstract
Background: To evaluate disease control, overall survival and prognostic factors in patients with locally recurrent
rectal cancer after IOERT-containing multimodal therapy.
Methods: Between 1991 and 2006, 97 patients with locally recurrent rectal cancer have been treated with surgery
and IOERT. IOERT was preceded or followed by external beam radiation therapy (EBRT) in 54 previously untreated
patients (median dose 41.4 Gy) usually combined with 5-Fluouracil-based chemotherapy (89%). IOERT was delivered
via cylindric cones with doses of 10–20 Gy. Adjuvant CHT was given only in a minority of patients (34%). Median
follow-up was 51 months.
Results: Margin status was R0 in 37%, R1 in 33% and R2 in 30% of the patients. Neoadjuvant EBRT resulted in
significantly increased rates of free margins (52% vs. 24%). Median overall survival was 39 months. Estimated 5-year
rates for central control (inside the IOERT area), local control (inside the pelvis), distant control and overall survival
were 54%, 41%, 40% and 30%. Resection margin was the strongest prognostic factor for overall survival (3-year OS
of 80% (R0), 37% (R1), 35% (R2)) and LC (3-year LC 82% (R0), 41% (R1), 18% (R2)) in the multivariate model. OS was
further significantly affected by clinical stage at first diagnosis and achievement of local control after treatment in
the univariate model. Distant failures were found in 46 patients, predominantly in the lung. 90-day postoperative
mortality was 3.1%.
Conclusion: Long term OS and LC can be achieved in a substantial proportion of patients with recurrent rectal
cancer using a multimodality IOERT-containing approach, especially in case of clear margins. LC and OS remain
limited in patients with incomplete resection. Preoperative re-irradiation and adjuvant chemotherapy may be
considered to improve outcome.
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Despite major improvements in the treatment of pri-
mary rectal cancer, namely the introduction of neoadju-
vant (chemo)-radiation and total mesorectal excision,
locoregional recurrences still develop in about 5-15% of
cases [1,2]. About 50% of these patients suffer from lo-
cally confined disease without distant spread [3]* Correspondence: F.Roeder@dkfz.de
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reproduction in any medium, provided the oraccompanied by high morbidity [4] and therefore repre-
sent candidates for a curative intent local treatment ap-
proach including surgical resection.
However, complete resections are difficult to achieve,
because tumor growth is not confined to the initial ana-
tomical compartments due to previous surgery [5]. The
addition of external beam radiotherapy (EBRT) is also
often limited, because many patients have already been
exposed to radiotherapy during primary treatment and
therefore the tolerance of the surrounding structures
restricts dose prescription.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and treatment characteristics
Patient characteristics n % n %
Age at FD (yrs) Prior RT
Median 56 yes 43 44
Min 30 no 54 56
Max 74 Median dose (Gy) 50
Age at IORT (yrs) Distant metastasis prior to IORT
Median 60 History of resected metastasis 13 13
Min 31 Resection during present surgery 5 5
max 78 both 2 2
none 77 79
Time FD to IORT (mo)
Median 30 Type of present surgery
Min 5 AR 21 22
Max 181 APR 38 39
Pelvic exenteration/bone resection 32 33
Gender other 6 6
Male 59 61
Female 38 39 Resection Status (present surgery)
R0 36 37
No. of recurrence R1 32 33
First 83 86 R2 29 30
Multiple 14 14
EBRT in relation to present surgery
T stage at FD Neoadjuvant RT 6 6
T1 6 6 Neoadjuvant RCHT 40 41
T2 28 29 Adjuvant RT 0 0
T3 57 59 Adjuvant RCHT 8 8
T4 5 5 none 43 44
unknown 2 2
Adjuvant CHT
N stage at FD Yes 33 34
N0 54 56 No 64 66
N+ 41 42
unknown 2 2 IORT dose (Gy)
<10 1 1
M stage at FD 10 32 33
M0 92 95 12 18 19
M1 (all resected) 5 5 15 35 36
18 8 8
UICC stage at FD 20 3 3
I 28 29
II 25 26 IORT electron energy (MeV)
III 37 38 Median 8
IV 5 5 Min 6
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Table 1 Patient and treatment characteristics (Continued)
Unknown 2 2 Max 18
Type of primary surgery IORT cone size (cm)
AR 65 67 Median 6.5
APR 27 28 Min 5
Local excision 5 5 Max 10
n: number of patients, %: percentage, FD: first diagnosis, yrs: years, Min: minimum, Max: maximum, IORT: intraoperative radiation therapy, mo: Months, No.:
number, UICC: Union internationale contre le cancer, RT: radiotherapy, AR: anterior resection, APR: abdominoperineal resection, R0: complete resection without
microscopic residual disease, R1: microscopic residual disease, R2: gross residual disease, EBRT: external beam radiation therapy, RCHT: radiochemotherapy, CHT:
chemotherapy, Gy: Gray, MeV: mega electron volts, cm: centimeter.
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theoretically offer some advantages. First, the tumor bed
representing the target volume, can be easily defined
and restricted in size as no margins accounting for inter-
fraction movements have to be added. Second, dose lim-
iting structures like small bowel can be removed from
the radiation field and protected from radiation side
effects [6].
For these reasons, curative intent therapy for patients
with recurrent rectal cancer included IOERT at our in-
stitution since 1991. In patients without prior irradiation
IOERT was preceeded or followed by EBRT, otherwise
IOERT was used as sole radiation treatment. The aim of
the current analysis was to evaluate the clinical results
in terms of disease control, overall survival and toxicity
as well as prognostic factors in a retrospective manner.
Methods
Between 1991 and 2006 a total of 113 patients suffering
from locally recurrent rectal have been treated by sur-
gery and IOERT at our institution. All patients gave writ-
ten informed consent. 16 patients were excluded from
analysis due to irresectable distant spread at the time of
surgery or missing follow-up data. Patients with a his-
tory of prior metastasectomy or complete surgical re-
moval of distant metastases during present surgery were
included into the analysis. Patients charts and reports
were reviewed to obtain patient and treatment charac-
teristics. Regular follow-up examinations took place at
our institution or at the referring centers. In case of
missing follow-up, data was completed by calling the pa-
tient or the treating physician. The median follow-up for
the entire cohort was 33 months (1–187 months) and
51 months in surviving patients.
The median time from first diagnosis to current treat-
ment was 30 months (5–181 months). 83 patients were
treated for their first local recurrence, 14 had multiple
ones. 43 patients (44%) have had prior radiotherapy to
the pelvis. For detailed characteristics of patients and
treatment see Table 1. In general, local recurrence was
discovered by routine follow-up or development of
symptoms. It was confirmed histologically in themajority of patients before surgery, however in some
cases diagnosis was based upon progressive growth on
repeated CT- or MRI scans. Patients were scheduled for
this treatment approach, if the risk for close or positive
margins seemed high according to the surgeons assess-
ment of preoperative imaging or after multidisciplinary
discussion, especially if pelvic side wall or sacral involve-
ment was present, whereas patients with limited, mainly
intraluminal recurrences confined to the anastomotic re-
gion were usually treated with surgery alone. In all but
two patients a radical resection was intended. Different
surgical procedures were used at the discretion of the
treating surgeon. In general, a trend to more extensive
surgery including pelvic exenteration and partial resec-
tion of sacral bone was seen over time. In patients with-
out a history of prior irradiation, surgery and IOERT
were proceeded or followed by EBRT with a median
dose of 41.4 Gy (range 15 to 54 Gy), usually in combin-
ation with simultaneous 5-FU based chemotherapy
(89%). Assuming, that the biological effect of the large
single dose used in IOERT is considered to be equivalent
to 1.5-2.5 times the same total dose of fractionated RT
[7], the EBRT dose of 41.4 Gy was chosen at the begin-
ning of our IOERT program with the idea to reach dose
escalation in the high risk area by the combination ap-
proach, while reducing late effects resulting from EBRT
(i.e. small bowel obstruction) and IOERT (i.e. neur-
opathy) by combining moderate doses of each treatment
as described in a previous publication by Eble et al. [8].
This concept emerged over time and since 2003, all uni-
rradiated patients with recurrent rectal cancer were trea-
ted with EBRT doses of 45 to 54 Gy. Patients who
received EBRT at our institution were usually treated in
prone position on a belly board with a three-field tech-
nique, using three-dimensional conformal treatment
planning routinely since 1995. The target volume
included the entire tumor region, the perirectal, presa-
cral and internal iliac node regions. Adjuvant chemo-
therapy was given only in a minority of patients (34%) at
the discretion of the treating medical oncologist.
The technique of IOERT used at our institution has
been described in detail earlier [6]. Briefly, IOERT was
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grated linear accelerator capable of delivering 6–18 MeV
electrons. The target volume was defined in correspond-
ence with the surgeon and included the high risk area
for positive margins or visible residual tumor with a
safety margin of 1 cm. The appropriate applicator was
the placed manually and attached to the surgical table.
Uninvolved radiosensitive tissues were displaced or
protected by lead shields. The moveable table was
located beneath the accelerator and properly aligned by
a laser air-docking system in a focus-surface distance
of 100 cm. In patients with additional EBRT, doses of
10–15 Gy were used intraoperatively, whereas patients
with a history of prior irradiation received 15–20 Gy.
Dose prescription was based on surgeons assessment of
margin status including increasing but not routine use
of intraoperative pathologic assessment of frozen sec-
tions during the overall study period. In general, higher
IOERT doses were applied in cases suspicious of positive
margins or residual disease according to the surgeons
assessment. The dose was prescribed to the 90%-isodose.
Central control (CC), local control (LC), distant control
(DC), and overall survival (OS) were calculated from the
date of surgery using the Kaplan-Meier method. CC and
LC were defined as absence of tumor regrowth or pro-
gression inside the IOERT area or the pelvis, respect-
ively. In patients without further assessment of LC e.g.
after development of distant spread, the date of the last
information about the local status was used for calcula-
tion. Differences in subgroups were tested for statistical
significance by the log-rank test. Multivariate analysis
was performed using the Cox regression method. Rela-
tions between distinct parameters were tested forTime [months]















Figure 1 Central and Local Control (entire cohort).significance by the Chi-square test. Differences were
considered statistically significant for a p-value of ≤ 0.05.
The study is in compliance with the Declaration of
Helsinki (Sixth Revision, 2008). Furthermore the study
was approved by the Independent Ethics Committee of
the Medical Faculty Heidelberg (Ref. Nr.: S-164/2012).
Results
Surgery
Complete resection, defined as microscopic negative re-
section margins in the final histopathological assess-
ment, was achieved in 36 patients (37%), whereas
32 patients (33%) suffered from microscopic and
29 patients (30%) from macroscopic residual disease.
The rate of complete resections was significantly linked
to the use of neoadjuvant EBRT (52% vs. 24%, p=0.007).
In contrast, the extent of the surgical procedure
(pelvic exenteration and/or bony resection vs. anterior/
abdominoperineal resection) had no statistically signifi-
cant impact on resection margin.
Central and local control
The three- and five-year estimated LC rates for the en-
tire cohort were 52% and 41%, respectively (Figure 1).
The corresponding figures for CC were 58% and 54%,
respectively. LC and CC rates were significantly corre-
lated with resection margins. Whereas patients with
complete resection (R0) showed three- and five-year LC
rates of 82% and 68%, the three-year rates dropped to
41% and 18% in case of microscopic or macroscopic re-
sidual disease (Figure 2, Table 2), respectively. Of note,
we found a significant difference in LC comparingTime [months]
















Figure 2 Local Control according to resection margin (R0 vs. R1
vs. R2).
Table 2 Univariate analysis of prognostic factors
Univariate analysis n % 3-y-LC p-value 3-y-DC p-value 3-y-OS p-value
all patients 97 100 52% 48% 52%
age
< 60 yrs 47 48 49% 0.329 50% 0.522 48% 0.619
≥ 60 yrs 50 52 55% 47% 55%
gender
male 59 61 44% 0.023 52% 0.779 53% 0.701
female 38 39 65% 42% 54%
time FD to rec
< 30 mo 48 49 49% 0.308 46% 0.389 43% 0.398
≥ 30 mo 49 51 55% 50% 61%
T stage (FD)*
T1/2 34 35 64% 0.13 61% 0.056 70% 0.045
T3/4 62 64 43% 40% 43%
N stage (FD)*
N0 54 56 61% 0.008 53% 0.047 60% 0.06
N+ 41 42 39% 42% 37%
UICC stage (FD)*
I/II 53 55 60% 0.015 55% 0.03 62% 0.046
III/IV 42 43 41% 41% 41%
resection margin
R0 36 37 82% < 0.001 55% 0.047 80% < 0.001
R1 32 33 41% 42% 37%
R2 29 30 18% 48% 35%
EBRT
yes 54 56 59% 0.062 49% 0.928 60% 0.18
no 43 44 41% 50% 43%
EBRT
neoadj RT 46 47 61% 0.067 51% 0.797 59% 0.284
no RT 43 44 41% 50% 43%
adj. CHT
yes 33 34 50% 0.817 54% 0.945 63% 0.745
no 64 66 54% 47% 45%
resection of met
yes 20 21 65% 0.358 35% 0.155 47% 0.484
no 77 79 49% 52% 54%
local control achieved
yes 52 54 not amendable 53% 0.2 55% 0.03
no 45 46 43% 52%
n: number of patients, %: percentage, 3-y-LC: three-year local control, 3-y-DC: three-year distant control, 3-y-OS: three-year overall survival, yrs: years, FD: first
diagnosis, rec: local recurrence, mo: months, *: based on 95 patients with known stage at first diagnosis, UICC: Union internationale contre le cancer, R0: complete
resection without microscopic residual disease, R1: microscopic residual disease, R2: gross residual disease, EBRT: external beam radiation therapy, RT:
radiotherapy, adj.: adjuvant, CHT: chemotherapy, met.: distant metastasis.
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Table 3 Prognostic value of resection margin for LC and
OS with or without EBRT (univariate analysis)
EBRT + IOERT IOERT alone EBRT + IOERT IOERT alone
3-y-LC 3-y-LC 3-y-OS 3-y-OS
R0 83% 79% 72% 100%
R1 52% 29% 43% 31%
R2 13% 21% 53% 17%
p-value <0,001 0,028 0,011 <0,001
LC: local control, OS: overall survival, EBRT: external beam radiation therapy,
IOERT: intraoperative electron radiation therapy, 3-y-LC: three-year local
control, 3-y-OS: three-year overall survival, R0: complete resection without
microscopic residual disease, R1: microscopic residual disease, R2: gross
residual disease, %: percentage.
Time [months]













Figure 3 Overall Survival (entire cohort).
0,8
1,0
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ease in univariate analysis (p=0.013). The influence of re-
section margins on LC remained statistically significant
after correction for the use of additional EBRT (Table 3).
Further on, female gender, negative nodal status and low
clinical stage at first diagnosis were significantly corre-
lated with improved LC in univariate analysis. Trends to
improved LC were seen for the use of neoadjuvant EBRT
in general and for IOERT doses ≥15 Gy in patients with
microscopic residual disease (Table 2). In the multivari-
ate model, the strong impact of resection margin on LC
could be confirmed (Table 4), but none of the other fac-
tors remained statistically significant. Interestingly, the
time interval between first diagnosis and recurrence
reached statistical significance in the multivariate model,
although we did not found a significant impact in uni-
variate analysis. A trend to improved LC was observed
for the use of additional EBRT in the multivariate
model.
Overall survival
We found a median estimated OS of 39 months, trans-
ferring into three- and five-year estimated OS rates of




Local control Overall Survival
hazard ratio p-value hazard ratio p-value
time FD to rec
< 30 months 1 1
≥ 30 months 0.95 (0.92-0.98) 0.04 0.98 (0.96-1.01) 0.221
resection margin
R0 1 1
R1 7.12 (2.29-22.12) 0.001 10.12 (3.76-27.27) < 0.001
R2 23.25 (7.22-74.79) < 0.001 13.04 (4.44-38.38) < 0.001
FD: first diagnosis, rec: local recurrence, R0: complete resection without
microscopic residual disease, R1: microscopic residual disease, R2: gross
residual disease values in parentheses: 95% confidence intervals.influenced by resection margins. Whereas patients with
microscopic complete resection showed very favourable
three- and five-year OS rates of 80% and 63%, the three-
and five-year rates dropped to 36% and 11% in case of
incomplete resection, respectively (Figure 4). In contrast
to LC, we did not observe a difference in OS according
to the extent of residual disease. Again, the influence of
margin status remained statistically significant after cor-
rection for the use of additional EBRT (Table 3). OS was
further significantly affected by T stage and clinical stage
at first diagnosis in univariate analysis. A trend toTime [months]














Figure 4 Overall Survival according to resection margin (R0 vs.
R1 vs. R2).
Time [months]















Figure 5 Overall survival according to local control after
current treatment (locally controlled vs. local failure).
Table 5 Distribution of distant metastases




lymph node° 5 11
bone 4 9
brain 2 4
multiple sites 4 9
n: number of patients, %: percentage, *: based on 46 patients with distant
failure after current treatment, °: non-regional.
Table 6 Complications and toxicity
Complications and Toxicity‘ n %
wound healing disturbance 19 20
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diagnosis (Table 2). In the multivariate model, resection
margin remained the only factor with significant impact
on OS (Table 4). If patients with an achievement of local
control were compared to patients with a re-recurrence
after IOERT, a significant benefit in terms of OS was
observed, which manifested after 3 years (Figure 5).
Distant control
The estimated three-and five-year DC rates for the en-
tire cohort were 48% and 40%, respectively (Figure 6).Time [months]













Figure 6 Distant Control (entire cohort).Resection margin, nodal status at first diagnosis and
clinical stage at first diagnosis were significantly asso-
ciated with DC in univariate analysis (Table 2). A trend
was seen for T stage at first diagnosis. In the multivariate
model only resection margin was significantly associated
with DC. Trends could also be found for the time inter-
val between first diagnosis (p=0.074) and recurrence and
for a history of metastasectomy (p=0.1). Of note, the
first occurrence of distant metastasis after the present
treatment was most frequently located in the lung (37%)
(Table 5).
Toxicity
The 90-day perioperative mortality rate was 3.1%. A
total of 80 complications occurred in 57 patients (59%).
The most common complications were postoperativeabscess or fistula 16 16
hemorrhage 6 6
ureteral stenosis 3 3
anal stenosis 2 2
ileus 3 3
neuropathy (incl. chronic pain) 8 8
urinary retention (transient) 9 9
urinary retention (persistent) 3 3
delayed gastrointestinal passage 3 3
perineal hernia 1 1
arterial catheter abcess 1 1
severe sphincter insufficiency 1 1
urinary leakage 1 1
compartment syndrome 1 1
pleural effusion 1 1
venous thrombosis 1 1
pulmonary embolism 1 1
N: number of patients, %: percentage, ‘: multiple events in some patients.
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tion, which have been observed in 20% and 16% of the
patients, respectively. These complications caused also
the majority (77%) of the 22 surgical re-interventions
(including incisions or drainage procedures). Another
common side effect was urinary retention, which was
found in 12% of the patients, but resolved after a short
time period in the majority of cases. Peripheral neur-
opathy including severe chronic pain was observed in
8% of the patients (Table 6). Neuropathy was found in
11% of the patients receiving IOERT doses of ≥15 Gy
compared to 6% in patients with <15 Gy, but this differ-
ence was not statistically significant.Discussion
Improvements in multimodality treatment of primary
rectal cancer resulted in a reduction in local recurrences,
however considering the widely exhausted tolerances of
the surrounding tissues by previous surgery and radio-
therapy, their treatment has become even more challen-
ging and sometimes has led to a nihilistic approach
considering this situation as palliative only. In contrast,
this report describes a large single-center experience
using a multimodality IOERT-containing regimen, which
shows that long term LC and OS is achievable in a sub-
stantial proportion of patients, although conclusions
should be drawn with caution regarding the known lim-
itations of retrospective analyses in general and espe-
cially in terms of possible selection biases.
Conservative treatment approaches including palliative
EBRT usually result in a median survival <12 months
and 5-year OS rates <5% [3,9]. With surgery alone,
5-year OS rates in the range of 20-35% [10-13] have
been observed if free margins were achieved, but long
term survival was almost absent in patients with residual
disease [9,10,14]. Because the rate of complete resec-
tions in patients undergoing surgery is only in the range
of 30-45% [3], additional irradiation has been investi-
gated. Response to neoadjuvant EBRT has been shown
to result in increased complete resection rates andTable 7 Results after IORT in R0 and R+ patients (only series
Study R0
n 5-year OS 5
Haddock et al. (2011) [4] 226 46 7
Dresen et al. (2008) [5] 84 48 6
Lindel et al. (2001) [19] 25 40 5
Alektiar et al. (2000) [20] 53 36 4
Wiig et al. (2002) [27] 18 60 7
Current study 33 63 6
IORT: intraoperative radiation therapy, n: number of patients, R0: complete resectio
disease, 5-year OS: 5-year overall survival [percentage], 5-year LC: 5-year local contrdecreased local failure rates in primary rectal cancer [1,15].
Similar effects have been also described for recurrent
rectal cancer [5,14]. However, the dose of conventionally
fractionated EBRT required for control of residual disease
is estimated to be ≥60 Gy and therefore exceeds small-
bowel tolerance already in previously not irradiated
patients [16,17]. Further on, an increasing number of
patients suffering from recurrent rectal cancer had already
been previously irradiated and concerns about toxicity pre-
vented many groups from the use of external beam re-
irradiation [4]. Therefore IOERT has been investigated be-
cause of the opportunity to remove critical organs at risk
from the target volume [6]. In cases without prior irradi-
ation, the combination with EBRT also allows safe dose es-
calation to overcome the dose limitations of EBRT alone as
shown in advanced primary rectal cancer [18].
In our series, patients without prior irradiation
received EBRT combined with 10–15 Gy IOERT.
Patients with prior irradiation have been treated with
IOERT alone. No re-irradiation was performed. We
observed a median survival of 39 months with a 5-year
OS rate of 30% and a 5-year LC rate of 41%. In patients
with microscopic complete resection, very favourable
5-year OS and LC rates of 63% and 68% were found. In-
complete resection (microscopic or gross) was clearly
associated with a worse outcome (5-year OS and LC
rates of 11% and 19% for the combined group, respect-
ively). Our results compare favourably with the series
using surgery alone, especially in patients with com-
plete resection and are in line with the findings of
other groups investigating IOERT-containing approaches.
Haddock et al. [4] described the same 5-year OS of 30%
and an extraordinary 5-year LC rate of 72% in the largest
series ever published. Dresen et al. [5] found a 5-year OS
of 31.5% and a 5-year LC rate of 50% in a large cohort
from the Netherlands. Lindel et al. [19] observed 3-year
OS and LC rates of 27% and 31% in a series from MGH
and Alektiar et al. [20] described 5-year OS and LC rates
of 23% and 39% in a MSKCC series using HDR-IORT.
However, resection margin remained the strongest
prognostic factor for LC and OS in our and other major>50 patients included)
R+
-year LC n 5-year OS 5-year LC
2 380 27/16 (R1/2) 68
9 63 12 29
6 24 14 17
3 21 7 (R1) 16 (R1)
0 41 20/0 (R1/2) 50/0 (R1/2)
8 64 11 19
n without microscopic residual disease, R+: microscopic or gross residual
ol [percentage], R1: microscopic residual disease, R2: gross residual disease.
Roeder et al. BMC Cancer 2012, 12:592 Page 9 of 11
http://www.biomedcentral.com/1471-2407/12/592series (Table 7). Obviously, IOERT does not thoroughly
compensate for an incomplete resection, with 5-year OS
rates of 36-63% and LC rates of 43-72% after micro-
scopic complete resection compared to 5-year OS rates
of roughly 10-30% after incomplete resection. Therefore
efforts should be made to increase the rate of R0 resec-
tions. We observed a significantly increased rate of free
margin resections in patients who were able to receive
neoadjuvant EBRT. Dresen et al. [5] described a similar
association and Saito et al. [12] found a statistically
increased LC and even OS rate after neoadjuvant EBRT
compared to surgery alone. Undoubtly, the use of EBRT
is feasible in previously untreated patients, but given the
somewhat disappointing results in previously irradiated
patients with incomplete resection using IOERT alone in
our and other series [5,21,22], renewed interest should
be paid to the possibility of re-irradiation. In contrast to
major concerns about severe side effects, re-irradiation
with moderate doses of 30–40 Gy has been associated
with acceptable toxicity [23-26], if restricted target
volumes were used and the interval to previous irradi-
ation was >6 months. In these four reports focussing on
reirradiation, a total of 270 previously irradiated patients
have been included and received conventional or hyper-
fractionated EBRT with median doses ranging 23.4 to
40.8 Gy, mainly combined with concurrent chemother-
apy. Resection rates varied from 33% [25] to 75% [23].
Two groups also used IORT with median doses of 10–15
Gy in 50% of the resected patients [23,26]. Median follow
up times ranged from 24 months to 82 months [23-26].
Severe (grade 3/4) acute toxicity rates ranged from 4%-
28% [23-26] and severe late side effects were observed in
11%-26% [24-26]. The observed 5-year LC and 5-year OS
rates were 33-39% [24,26] and 19%-40% [23-26] for the
entire groups, respectively. In the subgroups of patients
with resection of recurrent disease (irrespective of mar-
gin status), the 5-year OS rates seemed improved with
22%-54% [23,25,26], compared to unresected patients
with 5-year OS rates of 0%-22% [23-26]. The best results
have been observed in patients with R0-resection after
re-irradiation with 5-year LC and OS rates of 69%-70%
and 67%-72% in the two series from Italy [23,24], in
which R0 resection was also strongly associated with LC
and OS in multivariate analysis.
Although considering probable variations in patient se-
lection given the wide range in the percentage of resected
patients and overall outcome in those reports, the pos-
sible benefit of neoadjuvant re-irradiation was consist-
ently mainly confined to patients achieving resectability
(especially with free margins), whereas outcome of
patients with gross residual disease or no resection at all
remained dismal. Therefore neoadjuvant re-irradiation
seem to improve outcome mainly by increasing the rate
and completeness of following surgery, which issupported by the strong and significant association be-
tween resection or margin status and overall survival in
uni- and/or multivariate analysis in all of series [23-26].
The value of neoadjuvant re-irradiation in terms of
increased resectability was also confirmed by Dresen
et al. [5], who described significantly increased rates of
complete resections after neoadjuvant re-irradiation,
which transferred into improved LC and OS in combin-
ation with IOERT compared to IOERT alone.
Assuming the dose, that can be safely delivered in pre-
viously irradiated patients with EBRT, is probably limited
to 30–40 Gy mainly due to bowel toxicity (which was
the main side effect in the large series published by
Mohiuddin et al. [25]), and the dose that can be safely
applied thereafter via IOERT (with the opportunity to
exclude bowel from the irradiation field) is probably lim-
ited to about 15 Gy mainly due to neuropathy [28], the
combination of both approaches might be the best idea,
as advocated by investigators from Mayo [4] and Eind-
hoven [5]. In summary, given the morbidity of uncon-
trolled locoregional disease and the finding from our
series, that the achievement of LC in general is asso-
ciated with significantly improved overall survival, the
consideration of external beam re-irradiation followed
by surgery and IOERT seems justified.
Unfortunately, patients with recurrent rectal cancer
are also at high risk for distant failure. We observed a
5-year-DC rate of 40% in our patients. Similar results
have been shown in the series from Mayo (5-year-DC
rate 47%) [4] and the Netherlands (5-year-DC 50%) [5],
in which adjuvant systemic treatment was also uncom-
mon. In contrast to primary rectal cancer patients, the
lung was the most common site in our cohort, probably
due to the changed venous drainage caused by the surgi-
cal intervention during primary treatment. Similar pat-
terns of distant failures were described by other
investigators [28]. This may indicate, that at least a sub-
stantial proportion of distant failures were caused
through disseminating tumor cells from the recurrence
rather than being linked to the primary disease. This as-
sociation is also supported by the prognostic value of re-
section margin for distant control in many series
including ours [4,5]. However, we also observed a statis-
tically significant impact of TNM stage in primary situ-
ation on outcome. Similar results were found by other
investigators [5,29]. This may indicate, that an unfavour-
able biology of the disease (expressed by a locally
advanced stage in primary situation) could also have
caused a worse outcome. We could not confirm the
value of adjuvant chemotherapy in our series, however
this result could have been biased because patients with
adverse prognostic factors were more likely to receive it.
Nevertheless, given the high rates of distant metastasis
including the changes in their patterns, the introduction
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assumption is also supported by Hashiguchi et al. [30],
who observed a significantly improved OS in patients
treated with adjuvant chemotherapy after resection and
IOERT.
Conclusion
In summary, multimodality treatment including surgery,
IOERT and EBRT resulted in encouraging LC and long
term OS in a substantial proportion of locally recurrent
rectal cancer patients, especially if free margins could be
achieved. Neoadjuvant EBRT in previously untreated
patients resulted in increased rates of complete resec-
tions, which remained the strongest prognostic factor
for disease control and overall survival. Currently we use
45–50.4 Gy in combination with chemotherapy followed
by surgery and IOERT with 10–15 Gy in patients with-
out prior irradiation. Given the limited results in previ-
ously irradiated patients after incomplete resection with
IOERT alone, additional re-irradiation should be con-
sidered in carefully selected patients, especially since
achievement of local control seemed crucial for long term
survival. Intensified adjuvant systemic treatment may be
warranted given the high numbers of distant failures.
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